Parainfluenza Virus in Hospitalized Adults: A 7-Year Retrospective Study

Elliott Russell, Amy Yang, Sydney Tardrew, Michael G Ison*

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background. Parainfluenza virus (PIV) is a cause of respiratory tract infection in children and the immunocompromised population, but its clinical manifestations, impact, and outcomes in hospitalized adults are not well studied. Methods. This retrospective study included adults (?18 years old) admitted to Northwestern Memorial Hospital or Prentice Women's Hospital (both in Chicago, Illinois) between 1 August 2009 and 31 July 2016 with a positive molecular test result for PIV. Epidemiologic, clinical, and outcomes data were collected from the enterprise data warehouse and patient electronic health records after institutional review board approval. Descriptive statistics were used to summarize the data. Results. A total of 550 adults with a positive molecular test for PIV were identified. Differences in seasonality, clinical presentation, and prevalence between the different PIV serotypes (PIV-1, PIV-2, and PIV-3) were identified. The most common signs/symptoms were cough (88%), productive sputum (55%), fever (63%), and dyspnea (49%). Of the patients administered antibiotics, 349 (79.6%) had no confirmed bacterial infection throughout their hospitalization. The average length of hospitalization was 7.7 days. Presence of bacterial coinfection (P = .01), fungal coinfection (P < .01), decreased body mass index (P = .03), and increased respiratory rate (P < .01) were associated with significant differences in mortality rates. Conclusions. PIV infection is associated with substantial morbidity in hospitalized adults. Such data will be useful in understanding the impact on epidemiology and outcomes if a PIV-specific vaccine becomes available. Furthermore, this highlights the need for novel preventive and therapeutic approaches to PIV infection.

Original languageEnglish (US)
Pages (from-to)298-305
Number of pages8
JournalClinical Infectious Diseases
Volume68
Issue number2
DOIs
StatePublished - Jan 7 2019

Fingerprint

Paramyxoviridae Infections
Retrospective Studies
Viruses
Coinfection
Hospitalization
Electronic Health Records
Research Ethics Committees
Respiratory Rate
Sputum
Bacterial Infections
Cough
Respiratory Tract Infections
Dyspnea
Signs and Symptoms
Epidemiology
Body Mass Index
Fever
Vaccines
Anti-Bacterial Agents
Morbidity

Keywords

  • Adults
  • Hospitalized
  • Parainfluenza
  • Virus

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Russell, Elliott ; Yang, Amy ; Tardrew, Sydney ; Ison, Michael G. / Parainfluenza Virus in Hospitalized Adults : A 7-Year Retrospective Study. In: Clinical Infectious Diseases. 2019 ; Vol. 68, No. 2. pp. 298-305.
@article{6f4d0ab9a6c84a7bbbde76e745044884,
title = "Parainfluenza Virus in Hospitalized Adults: A 7-Year Retrospective Study",
abstract = "Background. Parainfluenza virus (PIV) is a cause of respiratory tract infection in children and the immunocompromised population, but its clinical manifestations, impact, and outcomes in hospitalized adults are not well studied. Methods. This retrospective study included adults (?18 years old) admitted to Northwestern Memorial Hospital or Prentice Women's Hospital (both in Chicago, Illinois) between 1 August 2009 and 31 July 2016 with a positive molecular test result for PIV. Epidemiologic, clinical, and outcomes data were collected from the enterprise data warehouse and patient electronic health records after institutional review board approval. Descriptive statistics were used to summarize the data. Results. A total of 550 adults with a positive molecular test for PIV were identified. Differences in seasonality, clinical presentation, and prevalence between the different PIV serotypes (PIV-1, PIV-2, and PIV-3) were identified. The most common signs/symptoms were cough (88{\%}), productive sputum (55{\%}), fever (63{\%}), and dyspnea (49{\%}). Of the patients administered antibiotics, 349 (79.6{\%}) had no confirmed bacterial infection throughout their hospitalization. The average length of hospitalization was 7.7 days. Presence of bacterial coinfection (P = .01), fungal coinfection (P < .01), decreased body mass index (P = .03), and increased respiratory rate (P < .01) were associated with significant differences in mortality rates. Conclusions. PIV infection is associated with substantial morbidity in hospitalized adults. Such data will be useful in understanding the impact on epidemiology and outcomes if a PIV-specific vaccine becomes available. Furthermore, this highlights the need for novel preventive and therapeutic approaches to PIV infection.",
keywords = "Adults, Hospitalized, Parainfluenza, Virus",
author = "Elliott Russell and Amy Yang and Sydney Tardrew and Ison, {Michael G}",
year = "2019",
month = "1",
day = "7",
doi = "10.1093/cid/ciy451",
language = "English (US)",
volume = "68",
pages = "298--305",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "2",

}

Parainfluenza Virus in Hospitalized Adults : A 7-Year Retrospective Study. / Russell, Elliott; Yang, Amy; Tardrew, Sydney; Ison, Michael G.

In: Clinical Infectious Diseases, Vol. 68, No. 2, 07.01.2019, p. 298-305.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Parainfluenza Virus in Hospitalized Adults

T2 - A 7-Year Retrospective Study

AU - Russell, Elliott

AU - Yang, Amy

AU - Tardrew, Sydney

AU - Ison, Michael G

PY - 2019/1/7

Y1 - 2019/1/7

N2 - Background. Parainfluenza virus (PIV) is a cause of respiratory tract infection in children and the immunocompromised population, but its clinical manifestations, impact, and outcomes in hospitalized adults are not well studied. Methods. This retrospective study included adults (?18 years old) admitted to Northwestern Memorial Hospital or Prentice Women's Hospital (both in Chicago, Illinois) between 1 August 2009 and 31 July 2016 with a positive molecular test result for PIV. Epidemiologic, clinical, and outcomes data were collected from the enterprise data warehouse and patient electronic health records after institutional review board approval. Descriptive statistics were used to summarize the data. Results. A total of 550 adults with a positive molecular test for PIV were identified. Differences in seasonality, clinical presentation, and prevalence between the different PIV serotypes (PIV-1, PIV-2, and PIV-3) were identified. The most common signs/symptoms were cough (88%), productive sputum (55%), fever (63%), and dyspnea (49%). Of the patients administered antibiotics, 349 (79.6%) had no confirmed bacterial infection throughout their hospitalization. The average length of hospitalization was 7.7 days. Presence of bacterial coinfection (P = .01), fungal coinfection (P < .01), decreased body mass index (P = .03), and increased respiratory rate (P < .01) were associated with significant differences in mortality rates. Conclusions. PIV infection is associated with substantial morbidity in hospitalized adults. Such data will be useful in understanding the impact on epidemiology and outcomes if a PIV-specific vaccine becomes available. Furthermore, this highlights the need for novel preventive and therapeutic approaches to PIV infection.

AB - Background. Parainfluenza virus (PIV) is a cause of respiratory tract infection in children and the immunocompromised population, but its clinical manifestations, impact, and outcomes in hospitalized adults are not well studied. Methods. This retrospective study included adults (?18 years old) admitted to Northwestern Memorial Hospital or Prentice Women's Hospital (both in Chicago, Illinois) between 1 August 2009 and 31 July 2016 with a positive molecular test result for PIV. Epidemiologic, clinical, and outcomes data were collected from the enterprise data warehouse and patient electronic health records after institutional review board approval. Descriptive statistics were used to summarize the data. Results. A total of 550 adults with a positive molecular test for PIV were identified. Differences in seasonality, clinical presentation, and prevalence between the different PIV serotypes (PIV-1, PIV-2, and PIV-3) were identified. The most common signs/symptoms were cough (88%), productive sputum (55%), fever (63%), and dyspnea (49%). Of the patients administered antibiotics, 349 (79.6%) had no confirmed bacterial infection throughout their hospitalization. The average length of hospitalization was 7.7 days. Presence of bacterial coinfection (P = .01), fungal coinfection (P < .01), decreased body mass index (P = .03), and increased respiratory rate (P < .01) were associated with significant differences in mortality rates. Conclusions. PIV infection is associated with substantial morbidity in hospitalized adults. Such data will be useful in understanding the impact on epidemiology and outcomes if a PIV-specific vaccine becomes available. Furthermore, this highlights the need for novel preventive and therapeutic approaches to PIV infection.

KW - Adults

KW - Hospitalized

KW - Parainfluenza

KW - Virus

UR - http://www.scopus.com/inward/record.url?scp=85059502670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059502670&partnerID=8YFLogxK

U2 - 10.1093/cid/ciy451

DO - 10.1093/cid/ciy451

M3 - Article

C2 - 29961826

AN - SCOPUS:85059502670

VL - 68

SP - 298

EP - 305

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -